For Rectal Cancer, Adjuvant 5-FU-Based Chemo Does Not Improve Survival
the Cancer Therapy Advisor take:
Adjuvant fluorouracil-based chemotherapy does not improve survival or distant recurrences in patients with rectal cancer, according to a recent study published in The Lancet Oncology.
However, adjuvant chemotherapy may have some benefit in disease-free survival and distant recurrence for those patients with a tumor 10 to 15 cm from the anal verge.
Researchers led by Anne Breugom, MD, and Marloes Swets, MD, of Leiden University Medical Centre in the Netherlands compiled information from online databases in order to identify European randomized, controlled, phase 3 trials comparing observation with adjuvant chemotherapy after preoperative radiotherapy and surgery for patients with non-metastatic rectal cancer.
They conducted a meta-analysis of four trials that included data from 1,196 patients with stage II or III disease and who had resection.
The researchers found no significant difference in overall survival between patients who received adjuvant chemotherapy and those who underwent observation.
However, in subgroup analyses, patients with a tumor 10 to 15 cm from the anal verge had an improved disease-free survival when treated with adjuvant chemotherapy compared to observation.
“Further studies of preoperative and postoperative treatment for this subgroup of patients are warranted,” the authors concluded.
Adjuvant fluorouracil-based chemotherapy does not improve survival or distant recurrences in patients with rectal cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Immunotherapy in Glioblastoma: Peaks and Pits
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed